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Abstract
In a fraction of patients surgically treated for cleft lip/palate, excessive scarring disturbs maxillary growth and dento-alveolar
development. Since certain genes are involved in craniofacial morphogenesis as well as tissue repair, a primary defect
causing cleft lip/palate could lead to altered wound healing. We performed in vitro wound healing assays with primary lip
fibroblasts from 16 cleft lip/palate patients. Nine foreskin fibroblast strains were included for comparison. Cells were grown
to confluency and scratch wounds were applied; wound closure was monitored morphometrically over time. Wound closure
rate showed highly significant differences between fibroblast strains. Statistically, fibroblast strains from the 25 individuals
could be divided into three migratory groups, namely ‘‘fast’’, ‘‘intermediate’’, and ‘‘slow’’. Most cleft lip/palate fibroblasts
were distributed between the ‘‘fast’’ (5 strains) and the ‘‘intermediate’’ group (10 strains). These phenotypes were stable
over different cell passages from the same individual. Expression of genes involved in cleft lip/palate and wound repair was
determined by quantitative PCR. Transforming growth factor-a mRNA was significantly up-regulated in the ‘‘fast’’ group.
5 ng/ml transforming growth factor-a added to the culture medium increased the wound closure rate of cleft lip/palate
strains from the ‘‘intermediate’’ migratory group to the level of the ‘‘fast’’, but had no effect on the latter group. Conversely,
antibody to transforming growth factor-a or a specific inhibitor of its receptor most effectively reduced the wound closure
rate of ‘‘fast’’ cleft lip/palate strains. Thus, fibroblasts from a distinct subgroup of cleft lip/palate patients exhibit an
increased migration rate into wounds in vitro, which is linked to higher transforming growth factor-a expression and
attenuated by interfering with its signaling.
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Introduction
Cleft lip and/or palate (CLP) affects overall 1 in 700 live births
and represents the most common congenital facial malformation
in humans [1]. CLP results from a developmental failure in
growth, elevation and/or fusion of the palatal shelves, distinct
preformed viscerocranial structures during embryogenesis [2–4]. A
fraction of patients undergoing primary cleft (especially palatal)
surgery show, in comparison to unoperated patients or non-cleft
controls, severe disturbances in midfacial growth and dento-
alveolar development [5–8]. Given many factors involved in
treatment outcome, the etiopathogenesis of theses disturbances
cannot be adequately attributed to the size of the cleft, the
treatment protocol, or the individual growth pattern [9–12], but
are reportedly due to excessive scarring after primary cleft surgery
[9,13,14]. In such cases, it is believed that the persistence of tissue
remodeling and matrix contracture results in the formation of a
rigid collagen-rich tissue [15] that hinders normal maxillary
growth [16]. Interestingly, many genes reported to be involved in
syndromic and non-syndromic CLP [3] code for transcription
factors, growth factors as well as receptors that are known to play
key roles in wound repair [4,17–23]. Therefore, one might
speculate that a genetic predisposition causing CLP could result in
abnormal wound healing subsequent to cleft surgery, and as a
consequence influence midfacial growth in a subset of CLP
patients. Indeed, children with Van der Woude syndrome (VWS)
have an increased risk to wound complications following cleft
repair [24]. With 2% of all cases, VWS is the most prevalent
syndrome associated with CLP. The syndrome is caused by
mutations in IRF6 [25], a transcription factor involved in the
keratinocyte proliferation-differentiation switch [26] and hence in
wound repair. In the study cited above [24], 47% of VWS patients
developed wound complications after cleft surgery, whereas only
19% of non-VWS children were affected.
By far the largest proportion of CLP cases are nonsyndromic,
however [3], and surprisingly, the possibility that a fraction of
these might exhibit a clinically relevant susceptibility to abnormal
wound healing has not been examined so far. Up to date,
mutations and polymorphisms in at least two dozen genes have
been associated with nonsyndromic CLP [3], [27], and because of
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the high number of affected individuals, it seems impractical in the
near future to determine the precise genetic cause of the defect for
every single patient. Nevertheless, it would be highly desirable to
develop a simple method for identifying CLP patients at risk for
wound healing problems before they undergo major reconstructive
surgery. With this in mind, we asked whether cells isolated from
individual CLP patients might exhibit significant differences in
their wound healing behavior in vitro when compared both
relative to each other and to control cells from healthy donors. We
thus performed scratch wound assays with cultures of dermal
fibroblast strains that were established from lip tissue of 16 CLP
patients, excised during their first surgery at 3 months of age.
Human foreskin fibroblast strains obtained from 9 children (of
which 3 had phimosis) were used as controls. We tested in terms of
the rate of cell migration into the wound whether these fibroblast
strains were normally distributed or whether they fell into distinct
subgroups. Unbiased statistical tests revealed that based on wound
closure ability in vitro, fibroblasts from the 25 individuals could be
divided into three populations, namely ‘‘fast’’, ‘‘intermediate’’, and
‘‘slow’’ migratory groups. One third of the CLP fibroblast strains
comprised the ‘‘fast’’ migratory group, together with the three
phimosis samples. All other CLP strains except one fell into the
‘‘intermediate’’ group. Normal foreskin fibroblast strains were
distributed between the ‘‘intermediate’’ and the ‘‘slow’’ group.
In order to identify a possible cause for the observed differences
between groups, we next used quantitative RT-PCR to compare
the expression levels of various CLP candidate genes among
individual fibroblast strains. Interestingly, a significantly higher
mRNA expression was found for transforming growth factor alpha
(TGFA) in ‘‘fast’’ compared to ‘‘intermediate’’ and ‘‘slow’’
migrating strains. Finally, pharmacological studies with agonists
and inhibitors of the respective signaling pathway strongly
indicated that differences in TGF-a levels are indeed responsible
for the distinct migratory behavior of the various CLP fibroblast
strains.
TGF-a has been reported to control proliferation, differentia-
tion and carcinogenesis primarily of epithelial cells (for review, see
[23]), and to have a role in endochondral ossification [28]. Our
present results establish a function for TGF-a in the migration of
fibroblasts during wound closure in vitro. Moreover, since TGFA
is one of the best documented genetic modifiers of facial clefting in
humans [29], our current findings might point to a functional link
between craniofacial malformation and changed wound healing
behavior by dermal fibroblasts in a fraction of CLP patients.
Materials and Methods
Ethics statement
This work was performed according to the Ethical Principles for
Medical Research Involving Human Subjects as defined by the
World Medical Association (Helsinki Declaration). Isolation of
human cleft lip (from infants three months of age) and foreskin
biopsies (from 2–5 year old boys) for this study has been approved
by the Kantonale Ethikkommission Bern, Switzerland (permission
number: 170-10). Written consent was obtained from the parents
of the children.
Isolation of human fibroblasts and cell culture
Fresh lip tissue samples, originating from the border between
facial skin and oral mucosa, were obtained from CLP patients
during surgical closure of the lip at the age of three months.
Foreskin tissue samples were obtained from two to five year old
boys during routine circumcisions. Tissue was wrapped into sterile
cloth wetted with sterile saline, and processed within less than one
hour after surgery.
Individual tissue samples (about 0.5 cm321.5 cm3) were placed
in a 10 cm culture dish in 20 ml serum-free Dulbecco’s modified
Eagle’s medium (DMEM; Gibco/Life Technologies, Lu-
BioScience, Lucerne, Switzerland) containing antibiotics/antimy-
cotics (Gibco). They were cut into tiny pieces (,1 mm3) with
scissors, transferred into a 6 cm culture dish containing 5 ml
collagenase D (from Clostridium histolyticum; Roche Diagnostics,
Rotkreuz, Switzerland; 1 mg/ml in DMEM), and placed at 37uC
in the CO2-incubator for 2 hours. Remaining pieces were minced
with tweezers for about 15 minutes. 5 ml DMEM containing 10%
fetal calf serum (Gibco) was added, and the suspension was
triturated for about 10 minutes. After a brief centrifugation at
1100 rpm to remove debris, the supernatant was centrifuged 5
minutes at 2000 rpm. The cell pellet was resuspended in 20 ml
10% FCS/DMEM and transferred into two 10 cm culture dishes
(10 ml per dish), which were placed in the CO2-incubator. After
48 hours, the medium was changed. After reaching confluency 7
days later, each culture dish was trypsinized and split onto 5 new
10 cm-dishes (in 10 ml 10% FCS/DMEM). The culture media
were changed every 3–4 days. Confluent cultures were trypsinized;
cells were frozen in 10% dimethyl sulfoxide/20% FCS/DMEM
(cells from one dish per vial in 1 ml freezing medium) and stored in
the gas phase of a liquid nitrogen tank.
Human primary oral mucosal fibroblasts used for additional
comparison were obtained from Dr. Reinhard Gruber (Depart-
ment of Oral Surgery and Stomatology, University of Bern). These
cell strains had been isolated, after approval (Kantonale
Ethikkommission Bern) and informed consent, from palatal tissue
grafts obtained during gingiva recession coverage in healthy adults
as published [30].
All experiments were performed with cells from the first to forth
passage. Some strains showed senescent cells starting from the fifth
passage; thus later passages were not used for measurements.
Wounding model in vitro (‘‘scratch wound assay’’)
Human fibroblasts were plated into 6-well culture dishes
(CellstarH, Greiner Bio-One, Huberlab AG, Aesch, Switzerland;
700,000 cells/well) in 10% FCS/DMEM and placed at 37uC in
the CO2-incubator overnight. The next morning, pipet tips were
cut obliquely (45u angle) with a sterile razor blade. Wounds
,1 mm in width were applied by scratching the confluent
fibroblast monolayers with the trimmed pipet tips. Cells in
suspension were removed by aspiration. Phase contrast images
were taken at 0 hours, 5 hours and 24 hours after scratching, using
an inverted microscope (Leica DM IL LED) equipped with a 5x/
0.12 NA objective and a digital microscope camera (Leica
DFC420C, Twain Version 7.7.1.0). Wound closure areas were
measured with ImageJ (Software 1.48q, Rayne Rasband, National
Institutes of Health, USA) by subtracting the total amount (A) of
greyscale pixel counted in the cell-free area remaining after 24
hours from the initial wound area; hence: ‘‘Wound closure area’’
[pixel] =Ainitial – A24 hrs. Since scratch width varied to some extent
from one wound to the other, a ‘‘relative wound closure’’ (RWC)
area was calculated by normalizing the measured wound closure
area (in pixels) to the total area of the image, which covered
2.26106 pixels (169861296 pixels, or 2.0461.56 mm). Hence:
RWC [%]=wound closure area [pixel] 6 100 [%]/2.26106
[pixel], of which 100% is equivalent to 3.18 mm2.
Cell proliferation measurement
Proliferation rates of different CLP strains were determined
using a BrdU labeling reagent (Invitrogen, Camarillo, USA) and a
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Figure 1. Fibroblasts from CLP patients fall into statistically distinct groups based on wound closure in vitro. Fibroblast strains were
obtained from 16 CLP patients, 6 healthy individuals (foreskin; Fsk) and 3 patients with phimosis (Phim), and scratch wound assays were performed
in vitro (see Materials and Methods). Box plots show the percentage of relative wound closure after 24 hours (% RWC) and the distribution of the
collected data of at least three independent experiments (***p,0.001). (A) Box plots of the individual cell strains are marked at the bottom of the
graph by the initials of the patients; they cluster into three distinct migratory groups namely ‘‘fast’’, ‘‘intermediate’’ and ‘‘slow’’. The origin of strains
from the different proband groups is also indicated: Phimosis (Phim), cleft lip/and palate (CLP), normal foreskin (Fsk). See Tables S2 and S3 for
descriptive data and p-values, respectively. (B) Representative images of one strain from each of the three migratory groups, taken immediately after
TGF-a in Cleft Lip/Palate Fibroblast Migration
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biotin-streptavidin based staining kit (Invitrogen, Camarillo, USA).
Cells were seeded at 509000 cells/ml in a 24-well dish and cultured
overnight in 10% FCS/DMEM. On the next day, cultures were
incubated for 4 hours in sterile-filtered BrdU solution (1:100 in
10% FCS/DMEM), washed 362 minutes with PBS, and fixed
with 70% ethanol. Endogenous peroxidase was blocked with 3%
H2O2 for 10 min. BrdU positive nuclei were visualized using
biotinylated anti-BrdU, streptavidin-peroxidase and diaminoben-
dizine according to the manufacturer’s instructions. Hematoxylin
was applied for counterstaining. Images were captured as
described above. The ratio of cells in S-phase was determined
by the number of BrdU positive cells in relation to the total
number of cells per image. Statistical significance was determined
by a Student’s t-test. Differences with a value of p,0.05 were
considered significant.
Life imaging and directionality of cell migration
Scratch wounds were applied to fibroblast monolayers as
described above. Culture dishes were placed in a live imaging
climate chamber (Live Imaging Services, Basel, Switzerland)
supplied with 10% CO2 and kept at 37uC. Images were captured
every 2 minutes during 24 hours with ProgRes CapturePro
software by a ProgRes MFcool camera (Jenoptik, Jena, Germany),
using a 10x/0.25 NA objective on an Olympus CKX41 inverted
microscope. Images were stacked and converted into AVI format
using ImageJ software. Directionality was calculated by measuring
the euclidean distance (linear distance in pixels between the cell’s
starting point at the wound margin and the end position after 24
hours) relative to the accumulated distance (cell path in pixels
tracked by line segmentation) using ImageJ. Cell positions were
defined by the cell’s nuclei. For one strain of the ‘‘fast’’ and one of
the ‘‘intermediate’’ CLP group, directionality of 10 migrating cells
was determined. Statistical significance was determined by
Student’s t-test. Differences with a value of p,0.05 were
considered significant.
Pharmacological studies
To determine the optimal dose for each growth factor or
inhibitor, preliminary scratch wound assays were performed with
various concentrations using at least one fibroblast strain of each
CLP migratory group (‘‘fast’’ and ‘‘intermediate’’) before proceed-
ing with other cell strains. The concentrations were based on the
technical data provided by the manufacturers: 2, 5, and 20 ng/ml
for recombinant human TGF-a (SIGMA-Aldrich, Buchs, Swit-
zerland); 0.25, 0.5, and 2.5 mg/ml for neutralizing TGF-a
antibody (BioVision, Milpitas, USA); 5, 20, and 50 ng/ml for
recombinant human PDGF-CC (SIGMA-Aldrich, Buchs, Swit-
zerland). PD153035 (Stelleckchem, Houston, USA) was examined
at 150 nM, 600 nM and 1 mM, and Lapatinib (Stelleckchem,
Houston, USA) at 150 nM, 600 nM, 2 mM, and 5 mM. Stock
solutions of PD153035 and Lapatinib were prepared in DMSO
and diluted in serum-free DMEM before addition to the culture
media. Confluent cultures were pre-incubated with all reagents 3
hours before scratch wounds were applied. Each reagent was
tested on at least three randomly chosen cell strains per group.
The experiments were repeated twice.
Immunofluorescence staining
Wounded cell monolayers were fixed in 4% paraformaldehyde
diluted in PBS (150 mM NaCl, 20 mM Na phosphate, pH 7.4),
then blocked and permeabilized with 3% BSA/0.2% TritonX-
100/PBS for 30 minutes at room temperature. Cell cultures were
incubated for 45 minutes with mouse monoclonal anti-vinculin
antibody (SIGMA-Aldrich, Buchs, Switzerland) diluted 1:1000 in
3% BSA/0.2% Triton/PBS. Prior to adding the secondary
antibody, samples were washed three times for 5 minutes with
0.5% BSA/0.03% TritonX-100/PBS. TRITC-phalloidin (1 mg/
ml; SIGMA-Aldrich, Buchs, Switzerland) was added along with
secondary antibody Alexa FluorH 488 goat anti-mouse IgG
(Invitrogen, Life Technologies, LuBioScience, Lucerne, Switzer-
land; diluted 1:1000 in BSA/Triton/PBS). Cells were washed
three times for 5 minutes with BSA/Triton/PBS and mounted in
PBS-buffered 90% glycerol containing DAPI (Roche, Basel,
Switzerland) at a concentration of 1 mg/ml. Images were captured
with ProgRes CapturePro software by a ProgRes CT3 camera
(Jenoptik, Jena, Germany), using a 40x/0.75 NA objective on an
Olympus BX-51 phase/fluorescence microscope equipped with a
xenon lamp (X-Cite, series 120PC Q, Ontario, Canada), and
fluorescence filters U-MWIBA3 for AlexaFluor 488, U-MWIGA3
for Alexa Fluor 568 and TRITC, and U-MNUA2 for DAPI.
The size and shape of focal adhesions from ‘‘fast’’ and
‘‘intermediate’’ CLP fibroblast strains was measured from vinculin
immunofluorescence micrographs by ImageJ. Images were thre-
sholded, and areas of interest corresponding to the front ends of
individual cells were selected manually. Thresholded particles (i.e.
vinculin-positive focal adhesions) were fitted with ellipses, and their
area, length, and aspect ratio was calculated individually. Of each
fibroblast strain, 250–400 focal adhesions from 12–15 cells were
measured and data averaged.
RNA extraction and cDNA synthesis
Human fibroblasts of the second passage were plated on a
culture dish in 10% FCS/DMEM and placed at 37uC in the CO2-
incubator. At 90% confluency, cells were washed with PBS. Total
RNA was isolated using the innuPREP RNA Mini Kit (Analytik
Jena AG; LifeScience, Jena, Germany). The extracted RNA was
dissolved in 80 ml of RNase-free distilled water and stored at 2
80uC until use. RNA quantification was performed using
Nanodrop 2000c (Thermo Scientific, Waltham, MA, USA).
For cDNA synthesis, 500 ng RNA in 14 ml ddH2O was tagged
with 1 ml Oligo(dT) 15 Primer (0.5 mg/ml; Promega, Du¨bendorf,
Switzerland) at 70uC during 5 minutes. Samples were placed for 5
minutes on ice prior to adding 5 ml M-MLV 5xbuffer (Promega,
Du¨bendorf, Switzerland), 1.25 ml dNTPS (10 mM; Promega,
Du¨bendorf, Switzerland), 3.25 ml ddH2O and 0.5 ml M-MLV
reverse transcriptase (Promega, Du¨bendorf, Switzerland). The
final solution was heated for 60 minutes at 40uC, followed by 15
minutes at 70uC to stop the reaction. Samples were placed for 5
minutes on ice, centrifuged and stored at 280uC. RNA extraction
was performed with all cell strains of the ‘‘fast’’ and ‘‘slow’’
migratory groups, whereas for the ‘‘intermediate’’ group, RNA
isolation was limited to six strains (2 Fsk, 4 CLP).
wounding (0 h) and 24 hours later (24 h). Area of scale bar corresponds to 10% RWC or 0.32 mm2. (C) Box plots of the median RWC values obtained for
all cell strains within each of the three migratory groups. (D) Two distinct migratory groups within the CLP patient cohort are evident after performing
a multiple comparisons test with the data collected from CLP fibroblast strains alone. The fibroblast strain derived from patient ‘‘BA’’ was considered
an outlier and therefore not included in this statistical analysis. See Tables S2 and S4 for the descriptive data and p-values, respectively. (E) When CLP,
Fsk and Phim cell strains were grouped separately, they corresponded to statistically distinct populations, although heterogeneity within the CLP
group was evident from the large variance.
doi:10.1371/journal.pone.0111752.g001
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Design of primers
All primers were individually designed and tested for their
specificity using the online Gene Bank database and the Primer-
BLAST software provided by the National Center for Biotech-
nology Information for human TGFB1, TGFB3, BMP7, FGF12,
EGF, TGFA, PDGFC, TGFBR2, FGFR1, EGFR, PDGFRB,
MET, JAG1, TNC, TNW, FN, COL1, COL3, MMP2, MMP9,
VCL, ACTA2, ADH1C, IRF6, RUNX2, SOX9 and GAPDH (see
Table S1). In the center of each probe sequence, an exon-exon
junction was placed to avoid non-specific fluorescent emission
derived from contaminating genomic DNA. The nucleotide
sequences and size of the primers are shown in Table S1. The
designed primers were purchased from Microsynth (Balgach,
Switzerland), diluted in ddH2O (10 mM) and stored at 220uC.
Real-time quantitative RT-PCR
Real-time quantitative RT-PCR was performed using 20 ml
total reaction volume containing 1xPowerSYBRH green (Lu-
BioScience, Lucerne, Switzerland), 0.5 mM forward/reverse
primers and 20 ng cDNA in ddH2O on a 7500 Real-Time PCR
System (Applied Biosystems, Carlsbad, CA, USA). Reactions were
performed in duplicates and repeated at least two times. Data were
analyzed by the DCt method [31]. Each Ct value was normalized
against that of GAPDH in the same reaction. After averaging all
DCt values for each target gene for an individual cell strain, the
relative mRNA expression (22DCt) was calculated.
Statistics
All statistical tests and graphs were performed and designed
using the software R (version 2.15.1). For each experiment, the
data were first tested for normality (Shapiro-Wilk test) and
homoscedasticity (Levene’s test). As a result to these tests, a
Kruskal-Wallis test was run followed by a pairwise Wilcoxon rank
sum test with p-value adjustment [32] for evaluating the
significance of differences between more than two strains (n
[wounds per strain] = 38) or migratory groups (k [strains per
group] $4). An unpaired two-sample Wilcoxon test was conduct-
ed to test the significance between two sub2/groups. Differences
with a value of p,0.05 were considered significant (*p,0.05,
**p,0.01, ***p,0.001). Boxplots of individual strains include the
averages of at least three independent measurements, whereas
boxplots that represent either population groups or subgroups
include the average per individual cell strain. Whiskers indicate the
maximum and minimum values measured.
Results
Human fibroblast strains of various origin exhibit
significant differences in their rate of wound closure
in vitro
Wound healing assays were performed in vitro with primary
human fibroblasts isolated from excess lip tissue of 16 cleft lip/
palate (CLP) patients, and with human foreskin fibroblasts derived
from 6 healthy boys (Fsk) and 3 patients with phimosis (Phim). All
these cell strains were obtained from infants (see Materials and
Methods). Note that lip and foreskin fibroblasts are comparable in
their tissue origin since they are both derived from a mucocuta-
neous zone (a border between epidermis and mucosa). Scratch
wounds were inflicted to confluent fibroblast monolayers on tissue
culture dishes. Wound areas were measured morphometrically at
time zero and after 24 hours, and for each fibroblast strain the
relative wound closure area (RWC; expressed as % of the total
area of the image, see Materials and Methods) was determined
from the average of at least three independent experiments, which
were performed with different passages from individual strains. A
Kruskal-Wallis test followed by an unbiased pairwise Wilcoxon
rank sum test with Benjamini & Yekutieli [32] correction for
multiple comparisons was then performed on the entire data set, in
order to determine whether the velocity of wound closure
(corresponding to the rate of cell migration into the wound) was
distributed normally between fibroblast strains, or whether they
fell into distinct populations. Indeed, fibroblasts derived from the
25 individuals of our cohort migrated with statistically distinct
speeds into the wounds inflicted in vitro; the mean ranks of the
RWC per cell strain were significantly different among the 25
individual strains (Kruskal-Wallis chi-squared = 541.8508, df = 24,
p,2.2610216; n = 38 per strain). Shapiro-Wilk normality test (p,
0.001), and Levene’s test (p.0.08) indicated that the assumptions
of Kruskal-Wallis test were respected.
Depending on the RWC, fibroblast strains could be divided into
three migratory groups, namely ‘‘fast’’, ‘‘intermediate’’, and
‘‘slow’’ (Fig. 1A, B; Table S2), which were significantly different
from one another. The p-values after multiple comparisons for the
individual strains are listed in Table S3. The ‘‘fast’’ group included
the 3 phimosis and 5 of the CLP strains. Their median RWC
ranged between 41.8% and 46.4%. In the intermediate group, for
which the RWC varied from 33.2% to 35.8%, 10 CLP and 3
normal foreskin strains were categorized. The slowest and smallest
group (RWC=26.1% –29.6%) was represented by 3 normal
foreskin strains and 1 CLP ‘‘outlier’’ (strain ‘‘BA’’). The migratory
phenotype of each fibroblast strain within a group was stable when
assays were repeated with different passages of cells from the same
individual, as evidenced by the small variance of the combined
measurements for individual strains (Fig. 1A). Statistically, these
results were also confirmed by one-way ANOVA (p,2.2610216)
followed by Tukey’s posthoc test using the means of each strain
(‘‘fast’’, n = 8; ‘‘intermediate’’, n = 13; ‘‘slow’’, n = 4) for each
migratory group (Fig. 1C; Table S2).
Fibroblasts derived from cleft lip/palate patients fall into
two distinct groups based on wound closure rate in vitro
A major aim of our study was to compare the cohort of CLP
fibroblast strains not only with healthy controls, but also among
each other, in order to see whether their migration rates were
normally distributed or rather fell into distinct subclasses. Indeed,
within the CLP cohort the mean ranks of the RWCs per cell strain
were significantly different (Kruskal-Wallis chi-
squared= 261.3335, df = 14, p-value ,2.2610216). Two distinct
CLP migratory sub-groups, ‘‘fast’’ and ‘‘intermediate’’, were
evident (Fig. 1D; Table S2) after conducting a pairwise Wilcoxon
Figure 2. Size of focal adhesions differs between the two CLP migratory groups. Immunofluorescence staining against vinculin, and
rhodamine-phalloidin staining for F-actin of migrating cells 24 h after scratch wounds were applied. Two randomly chosen strains from the ‘‘fast’’ (TL
and XB) and the ‘‘intermediate’’ (LP and ML) group, respectively, were included in the analysis. (A) The box plots indicate the area in mm2 covered by
individual vinculin positive focal adhesions at the front end of cells (n[cells per strain] = 12–15). The whiskers indicate the maximum and minimum
area per focal adhesion in a strain (***p,0.001). (B) Representative pictures from two strains depict the front end with the lamellipodium of individual
cells migrating into the wound. Typically, migrating cells of the ‘‘fast’’ CLP group form smaller focal adhesions in comparison to cells of the
‘‘intermediate’’ group. Scale bar, 10 mm.
doi:10.1371/journal.pone.0111752.g002
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rank sum test with Benjamini & Yekutieli [32] correction (see
Table S4). With a ratio of 5 out of 16, about one third of the CLP
strains had significantly greater RWCs than the remainder. The
median RWC was 44.2% for the ‘‘fast’’ CLP migratory group and
34.8% for the ‘‘intermediate’’ group. The only ‘‘slow’’ CLP strain
‘‘BA’’ was considered an outlier when assigned to the intermediate
group, and hence was not included in statistical analysis of the
CLP cohort.
Kruskal-Wallis test followed by a pairwise Wilcoxon rank sum
test also indicated that when data were grouped according to CLP,
Fsk and Phim, respectively, these subject groups represented
statistically distinct populations (Kruskal-Wallis chi-
squared= 27.2245, df = 2, p-value = 1.2610206) (Fig. 1E; Table
S2). Phim was the subject group with the highest median RWC
(44%). Fsk had the lowest RWC (29.0%), which was significantly
below the median RWC of Phim (p,3610206). The differences
between CLP (median RWC 37.1%) and both, Fsk and Phim
groups were also significant (p,0.001 and p,0.003, respectively).
However, one-way ANOVA, using the means of each strain within
the subject groups (CLP, k[strains] = 16; Fsk, k = 6; Phim, k = 3),
followed by Tukey’s posthoc test, revealed significant differences
between Fsk and Phim (p,0.003), but not between CLP and both
Fsk and Phim groups (p.0.05). These results from ANOVA were
a further indication for heterogeneity within the CLP group. To
confirm this notion, the two CLP groups specified above were
compared separately to normal foreskin fibroblasts (not shown in
graph). Indeed, the RWC values of the ‘‘fast’’ CLP group were
significantly different from those of the Fsk group (p = 0.012), but
not of the ‘‘intermediate’’ group (p= 0.167).
In summary, our results indicate that the majority of CLP
fibroblast strains (the ‘‘intermediate’’ group) migrates into wounds
in vitro at a similar velocity as normal infant foreskin fibroblasts,
whereas a minority of CLP strains (the ‘‘fast’’ group) exhibit
significantly enhanced migration rates.
Since donor age and tissue origin might affect the wound
healing rate in vitro, as an additional control we performed
scratch assays with oral mucosal (palatal) fibroblasts obtained from
three normal adult individuals. We found that one of the three
strains fell into the ‘‘intermediate’’ and two into the ‘‘slow’’
migratory group (Fig. S2). In any case, none of the normal adult
oral strains migrated at an increased rate like ‘‘fast’’ CLP lip
fibroblasts, providing additional evidence for the exceptional
properties of the latter.
Enhanced wound closure by ‘‘fast’’ CLP fibroblasts is due
to increased migration velocity
The difference in the speed of wound closure in vitro between
‘‘fast’’ and ‘‘intermediate’’ CLP fibroblast strains was not caused
by different rates of cell proliferation, since the proportion of cells
in S-phase during a 4 hour period of labeling with BrdU was
essentially the same for both groups (Figure S3). Direct counting of
number of mitoses per 24 hours from life movies of scratch assays
confirmed this result (not shown). Life imaging (see Movies S1 and
S2) further revealed that the average migration distance per cell
per 24 h in the wound area was almost twice as high for fibroblasts
from a ‘‘fast’’ compared to an ‘‘intermediate’’ CLP strain
(6026258 versus 3246114 mm; p,0.01), whereas the direction-
ality of cell movement was not significantly different (‘‘fast’’:
0.5560.22; ‘‘intermediate’’: 0.7160.20). Thus, these results show
that the enhanced speed of wound closure by the ‘‘fast’’ strains is
due to increased velocity of cell migration, but not to increased
proliferation rate or directionality of movement.
Focal adhesion size of migrating fibroblasts differs
between ‘‘fast’’ and ‘‘intermediate’’ CLP groups
Immunofluorescence staining for vinculin and F-actin was
conducted on wounded cultures to examine whether focal
adhesions of migrating fibroblasts at the wound edge differed
between ‘‘fast’’ and ‘‘intermediate’’ CLP strains. For this
experiment, two representative strains of each CLP group were
randomly chosen, stained, and evaluated. Vinculin positive focal
adhesions at and behind the front lamellipodium of individual
migrating cells were measured; we quantified the area (in mm2)
covered by single adhesion contacts. As shown in Fig. 2A, the
average size of focal adhesions was significantly smaller in
fibroblasts from ‘‘fast’’ migrating strains compared to strains of
the ‘‘intermediate’’ CLP group (p,7610209). Images showed in
addition that cells from ‘‘intermediate’’ strains tended to have
fewer but thicker stress fibers attached to their large focal
adhesions, whereas ‘‘fast’’ migrating fibroblasts had prominent
lamellipodia, and showed thinner and more evenly distributed
actin fibers connected to many small adhesion contacts (Fig. 2B;
Fig. S1). As expected, these observations indicate that focal
adhesion size and actin organization correlate with migratory
behavior and thus with wound closure ability of the respective
CLP strains in wounding assays.
Increased wound healing in vitro correlates with
changed expression of TGFA and PDGFC
We next asked whether and which genes known to be involved
in both facial morphogenesis and regeneration might be respon-
sible for the differences observed between fibroblast strains in their
speed of wound closure in vitro. Therefore, fibroblasts from the
second passage of individual strains were grown to near confluency
and their RNA was isolated. The mRNA expression of TGFB1,
TGFB3, BMP7, FGF12, EGF, TGFA, PDGFC, TGFBR2,
FGFR1, EGFR, PDGFRB, MET, JAG1, TNC, TNW, FN,
COL1, COL3, MMP2, MMP9, VCL, ACTA2, ADH1C, IRF6,
RUNX2, SOX9 was measured by qRT-PCR, normalized against
GAPDH, and statistically evaluated by Kruskal-Wallis followed by
a pairwise Wilcoxon rank sum test for multiple comparisons.
When comparing cell strains derived from the entire cohort (CLP,
Fsk, and Phim subject groups), we did not find significant
differences in expression level for most of these genes (not shown).
However, our results indicated that the mean rank of TGFA
mRNA expression was significantly higher (.2-fold; Fig. 3A) and
of PDGFC lower (.3-fold; Fig. 3B) in the ‘‘fast’’ migratory group
Figure 3. Different expression levels of TGFA, PDGFC, EGFR and PDGFRB in the three migratory groups. Expression levels were determined
for the various mRNAs by qRT-PCR and normalized relative to GAPDH. Results are represented by boxplots; whiskers indicate the maximum and the
minimum values in each group (*p,0.05; **p,0.01). (A) TGFA was significantly up-regulated in the ‘‘fast’’ migratory group. The difference between
the ‘‘intermediate’’ and ‘‘slow’’ migratory groups was also significant. (B) PDGFC was down-regulated in the ‘‘fast’’ migratory group compared to
‘‘slow’’ and ‘‘intermediate’’ migratory groups. The difference between the ‘‘slow’’ and ‘‘intermediate’’ migratory group was not significant. Expressions
levels of the respective receptors EGFR and PDGFRB: (C) The mRNA of EGFR showed roughly the same tendency, but was not significant. (D) PDGFRB
was significantly down-regulated in ‘‘fast’’ migratory group compared to the ‘‘intermediate’’ migratory group. Differences in expression level of the
same mRNAs were persistent when comparing the ‘‘fast’’ with the ‘‘intermediate’’ migratory group within the CLP cohort: (E) TGFA; (F) PDGFC; (G)
EGFR, and (H) PDGFRB.
doi:10.1371/journal.pone.0111752.g003
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Figure 4. Effect of TGF-a, anti-TGF-a, and EGFR/ERBB2-inhibitor on wound closure by ‘‘fast’’ versus ‘‘intermediate’’ CLP strains.
Boxplots depict the RWC in scratch wound assays at 24 h of ‘‘fast’’ (A, C, E) and ‘‘intermediate’’ (B, D, F) CLP strains, in either the absence (control; Ctrl)
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compared to the ‘‘intermediate’’ and ‘‘slow’’ groups. Interestingly,
genes coding for respective receptors of these growth factors
showed the same tendency, although differences were only
significant for PDGFRB (.2-fold, Fig. 3D), not for TGF-a
receptor EGFR (Fig. 3C).
When fibroblast strains from the CLP patient cohort were
evaluated separately, the difference in expression between ‘‘fast’’
and ‘‘intermediate’’ migratory groups was again significant for
both TGFA (.2-fold; Fig. 3E) and PDGFC (.3-fold; Fig. 3F).
The corresponding receptors EGFR (Fig. 3G) and PDGFRB (.2-
fold, Fig. 3H) exhibited the same trend.
Addition of exogenous TGF-a accelerates wound closure
by fibroblasts primarily from the ‘‘intermediate’’
migratory CLP group
In a first attempt to find out whether the observed differences in
TGF-a expression levels between ‘‘fast’’ and ‘‘intermediate’’ CLP
groups might be causally linked to the speed of wound closure by
individual fibroblast strains, we tested the effect of adding
exogenous growth factor to the cultures during the assay. Three
hours before wounds were inflicted to fibroblast monolayers, TGF-
a was added to the standard culture media at either 5 ng/ml or
20 ng/ml. The addition of 5 ng/ml TGF-a significantly increased
the RWC (,1.5-fold; p,7610205) in the ‘‘intermediate’’ CLP
group, whereas it had no effect in the ‘‘fast’’ group (Fig. 4A, B).
The higher concentration of TGF-a (20 ng/ml) caused an increase
in both groups, but less in the ‘‘fast’’ (,1.2-fold, p,7610203) than
in the ‘‘intermediate’’ (,1.4-fold, p,1610205) (Fig. 4A, B).
TGF-a neutralizing antibody decreases wound closure by
CLP fibroblasts
Since supplementing the culture media with exogenous TGF-a
stimulated wound closure, we asked whether the contrary effect
was achieved by administering TGF-a-neutralizing antibody to
the culture media. A significant decrease of the RWC was
observed with 0.5 mg/ml anti-TGF-a in both ‘‘fast’’ (,0.7-fold,
p,3610203) and ‘‘intermediate’’ (,0.7-fold, p,0.05) groups
(Fig. 4C, D). A concentration of 0.25 mg/ml anti-TGF-a did not
cause a significant decrease of the RWC in all strains, whereas
2.5 mg/ml was no more efficient than 0.5 mg/ml in inhibiting
wound closure (not shown). To confirm that the antibody indeed
blocked TGF-a activity, we also tested combinations of TGF-a
with anti-TGF-a. As we expected for the ‘‘intermediate’’ group,
the stimulating effect of 5 ng/ml TGF-a was abrogated when
or the presence of the following agents diluted in 10% FCS/D-MEM: TGF-a at 5 ng/ml (T5) or 20 ng/ml (T20); TGF-a neutralizing antibody at 0.5 mg/ml
(AntiT); Lapatinib at 5 mM (Lapa); TGF-a plus anti-TGF-a (T5+AntiT); or TGF-a plus Lapatinib (T5+Lapa; T20+Lapa) (*p,0.05, **p,0.01, ***p,0.001).
The micrographs show representative examples of scratch wound assays at 0 and 24 h in the absence or presence of the drugs indicated at the
bottom. Area of scale bar corresponds to 10% RWC or 0.32 mm2.
doi:10.1371/journal.pone.0111752.g004
Figure 5. Distinct CLP migratory groups persist under low serum conditions. The graphs show the RWC in scratch wound assays at 24 h in
0.3% FCS/DMEM (*p,0.05, **p,0.01, ***p,0.001). (A) Despite a general decrease of the RWC, ‘‘fast’’ and ‘‘intermediate’’ CLP groups could still be
distinguished under low-serum conditions. (B, C) Effect of exogenous TGF-a diluted at 5 ng/ml (T5) and 20 ng/ml (T20), as well as of 5 mM Lapatinib
(Lapa) on both CLP subgroups under low serum conditions in comparison to controls (Ctrl).
doi:10.1371/journal.pone.0111752.g005
TGF-a in Cleft Lip/Palate Fibroblast Migration
PLOS ONE | www.plosone.org 10 October 2014 | Volume 9 | Issue 10 | e111752
0.5 mg/ml TGF-a neutralizing antibody was added in addition to
the culture media (Fig. 4D). In the ‘‘fast’’ group, the RWC was
reduced by TGF-a plus anti-TGF-a to the same level as by anti-
TGF-a alone, indicating that the antibody was able to block both
endogenous and exogenously added TGF-a (Fig. 4C).
Inhibiting EGFR/ERBB2 signaling decreases wound
closure by CLP fibroblasts
To study the role of TGF-a in wound closure further, we tested
whether inhibiting the signaling by its receptor EGFR would
reduce wound closure ability in both CLP groups. To this aim,
first attempts were conducted with the specific EGFR tyrosine
phosphorylation inhibitor drug PD153035. For the ‘‘fast’’ group,
the reduction in RWC was rather small but significant (,0.9-fold,
p,1610204) at 600 nM in 10% FCS/DMEM. No effect was
measured with 600 nM or 1 mM PD153035 in the ‘‘intermediate’’
group (data not shown).
The EGF receptor (ERBB1) can either form homodimers or
heterodimerize with other members of the EGFR/ERBB super-
family, such as ERBB2 [33]. With this in mind, we tested an
EGFR/ERBB2 tyrosine phosphorylation inhibitor, namely Lapa-
tinib. A significant decrease of the RWC was measured with 5 mM
of this inhibitor for both groups relative to the controls (‘‘fast’’
,0.6-fold, p,8610206; ‘‘intermediate’’ ,0.7-fold, p,0.05)
(Fig. 4E, F). Further, we examined whether the effect of Lapatinib
persisted in presence of exogenously added TGF-a: Wounding
assays were performed after preincubating cultures with 5 or
20 ng/ml TGF-a in combination with 5 mM Lapatinib. The
relative wound closure was significantly decreased compared to
the controls in both groups, to approximatively the same level as
with Lapatinib alone (Fig. 4E, F). Interestingly, ‘‘fast’’ migratory
fibroblast strains were reduced to about the RWC of the
‘‘intermediate’’ group after administration of Lapatinib to the
culture media. This confirms again the contribution of the TGF-
a/EGFR signaling pathway to the existence of distinct CLP
migratory groups.
‘‘Intermediate’’ CLP group is stimulated by TGF-a under
low-serum conditions
All experiments with TGF-a and inhibitors described so far
were done in standard medium containing 10% serum, which
simulates conditions in a wound in vivo. Since serum contains
other growth factors (such as platelet-derived PDGF-BB) that
might independently or synergistically stimulate fibroblast migra-
tion in scratch wound assays, it was important to test whether
effects of TGF-a were persistent in low-serum conditions. Scratch
wound assays were conducted with CLP strains in 0.3% FCS/
DMEM culture media. Also in low serum, the difference in the
speed of wound closure between ‘‘fast’’ and ‘‘intermediate’’ CLP
groups was significant (p,4610205): The RWC of the ‘‘fast’’
Figure 6. Small effect of PDGF-CC on wound closure by fibroblasts in vitro. Boxplots represent the RWC in scratch wound assays at 24 h
(*p,0.05, **p,0.01) of ‘‘fast’’ (A) and ‘‘intermediate’’ (B) CLP strains in 0.3% FCS/DMEM in the absence (control; Ctrl) or the presence of PDGF-CC
diluted at either 5 ng/ml (PC5), 20 ng/ml (PC20) or 50 ng/ml (PC50). Micrographs show representative examples at 0 and 24 h in the absence (Ctrl) or
presence of PDGF-CC (P20; P50). Area of scale bar corresponds to 10% RWC or 0.32 mm2.
doi:10.1371/journal.pone.0111752.g006
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group was ,1.3-fold higher than the one of the ‘‘intermediate’’
group (Fig. 5A). Next we tested the wound closure ability after
addition of either TGF-a or Lapatinib to both groups. The
‘‘intermediate’’ group was rescued by 5 ng/ml TGF-a in terms of
the RWC (,1.3-fold, p,0.02; Fig. 5C). A significant but rather
small increase was measured for the ‘‘fast’’ group (,1.1-fold, p,
0.02; Fig. 5B). The higher concentration of TGF-a caused an
increase in both groups (‘‘fast’’ ,1.5-fold, p,2610203, ‘‘interme-
diate’’ ,1.2-fold, p,0.04; Fig. 5B, C). When lapatinib was
preincubated with cultures at 5 mM in low-serum media, the
RWC of both the ‘‘fast’’ and the ‘‘intermediate’’ group was
significantly decreased (p,0.01) (Fig. 5B, C). Thus, the effects of
TGF-a or 5 mM Lapatinib seen under high-serum conditions
could in essence been reproduced in medium containing only
0.3% FCS, although the RWCs were generally lower.
Small effects of PDGF-CC on wound closure by CLP
fibroblasts
As we have shown in Fig. 3, PDGFC and PDGFRB were also
differentially expressed between migratory groups, suggesting a
possible contribution of cellular PDGF-CC to wound closure in
scratch assays. Since PDGFC was more highly expressed in the
‘‘intermediate’’ group, however, we expected little effect of
exogenously added PDGF-CC in terms of changes in the RWC.
To minimize a possible contribution of PDGF-BB from serum, the
following experiments were conducted in low-serum conditions.
PDGF-CC was added to cultures at 5, 20, and 50 ng/ml in 0.3%
FCS/DMEM. For the ‘‘intermediate’’ group, the highest concen-
tration somewhat increased the speed of wound closure (,1.2-fold,
p,8610203; Fig. 6B); lower concentrations in the physiological
range did not have any effect. For the ‘‘fast’’ group, small increases
of the RWC were measured at 20 ng/ml (,1.2-fold, p,0.02) and
50 ng/ml (,1.1-fold, p,0.03), but not at 5 ng/ml. In summary,
high concentrations of PDGF-CC appeared to slightly stimulate
the speed of wound closure for both ‘‘intermediate’’ and ‘‘fast’’
migratory strains, but effects were small compared to TGF-a even
at 5 ng/ml.
Discussion
Fibroblasts are the most important cells in wound contraction,
granulation tissue formation and scarring [34]. During migration
into the wound, fibroblasts generate tractional forces, thus
transmitting mechanical stress to the extracellular matrix
[35,36]. Both, mechanical stress and TGF-b1 promote differen-
tiation of fibroblasts to myofibroblasts (reviewed in [37]). Mature
myofibroblasts synthesize extracellular matrix and contribute to
wound contracture, and thereby increase tension development in a
positive feedback loop [37]. Therefore, the initial extent of
fibroblast migration into the wound contributes to the later
differentiation of myofibroblasts and favors fibrogenesis. The
simple in vitro scratch wound assay used here has been shown to
reveal differences in migratory behavior between fibroblasts from
various sources that correlate with aberrant wound healing
in vivo. For example, fibroblasts isolated from keloid tissue were
reported to have significantly higher migration rates in scratch
wound assays than extralesional fibroblasts from the same
individual [38].
Using this in vitro wound healing assay, we asked whether the
migration rates of individual fibroblast strains from a cohort of
CLP patients were distributed normally, or whether they clustered
into statistically distinct groups. The CLP samples were age-
matched since the lip tissue used for isolating the cells was
obtained as a by-product of the standard surgery to close the cleft
in three months old infants; no biopsy procedure was required. Lip
tissue consists of a mucocutaneous zone, i.e. a border between skin
epidermis and mucosal epithelium. The same is true for foreskin;
thus these two tissues are roughly comparable. Age-matched
foreskin fibroblasts therefore appeared to be an acceptable if not
an ideal control in our experiments. We are aware that it would be
desirable to perform similar experiments with age-matched
fibroblasts on the one hand from normal lip tissue, and on the
other hand from pure oral mucosa [39]. However, for ethical
reasons it is impossible to obtain such tissues from healthy infants.
In any case, our comparison of CLP samples among each other is
valid without restrictions because they are all derived from exactly
the same location.
The majority of CLP lip fibroblast strains migrated with a
moderate speed into scratch wounds applied to cell monolayers
(‘‘intermediate’’ group), whereas about one third of the CLP
strains closed the wounds at a significantly higher rate (‘‘fast’’
group). Expectedly, fibroblasts from ‘‘fast’’ strains exhibited more
prominent lamellipodia and many but smaller focal adhesions.
Normal foreskin fibroblasts used for control were split between the
‘‘intermediate’’ and a third, ‘‘slow’’ migratory group. Interestingly,
the ‘‘fast’’ migratory group also included all three strains from
patients operated for phimosis. For individual fibroblast strains,
the reported phenotypes were stable over several cell passages,
indicating that they were due to cell-autonomous differences in
gene expression. We therefore measured the expression of a set of
genes associated with both CLP and wound healing, and found
that mRNA levels were significantly increased for growth factor
TGFA, and decreased for PDGFC, in the ‘‘fast’’ compared to the
other two migratory groups. The expression levels of EGFR and
PDGFRB, receptors for TGF-a and PDGF-CC, respectively,
followed the same tendency. Although produced by fibroblasts, the
major source of PDGFs is blood, where platelet derived PDGF-BB
reaches .10 ng/ml in human serum [40]. It is therefore safe to
assume that fibroblasts are exposed to high exogenous PDGF
concentrations both in wounds and in culture. In contrast, the
concentration of TGF-a in serum is very low (ca. 0.15 ng/ml in
human [41]). We therefore speculated that differences in
migratory speed between individual CLP fibroblast strains were
due to variations in the cell-autonomous production and activation
of TGF-a. Supporting this notion, the closure of scratch wounds
by ‘‘intermediate’’ migrating CLP fibroblast strains was acceler-
ated by addition of 5 ng/ml TGF-a to the culture medium,
whereas only higher concentrations had an effect on the ‘‘fast’’
migrating strains. Conversely, specific EGFR inhibitors and TGF-
a neutralizing antibodies reduced the speed of migration most
effectively for the ‘‘fast’’ strains.
Incidentally, TGFA was the very first gene to be implicated in
nonsyndromic CLP in humans [42], [43] and since then, many
studies have been conducted to corroborate this notion [29]. A
direct association of TGFA gene polymorphisms with CLP
remained inconclusive, however [29,44,45]. Therefore, this
growth factor is now considered to be a modifier rather than an
effector of the CLP phenotype. This is supported by a recent meta-
analysis including 29 studies, which provided a positive association
of the TGFA/TaqI polymorphism with CLP and suggested for
TGFA/BamHI polymorphism that persons carrying an A1 allele
may have a decreased risk of CLP [46]. However, it is not known
yet whether these TGFA polymorphisms are associated with gain
or loss of function. In the animal model, the secondary palate
develops normally in Tgfa null mice [47,48], although Tgfa is
expressed at the medial edge epithelium of fusing palatal shelves
[49], and TGF-a was shown to promote mesenchymal cell
migration and ECM synthesis in palatal cultures [50]. On the one
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hand, mice deficient for the TGF-a receptor gene Egfr show an
increased incidence of orofacial clefts [51], and on the other hand,
excess EGF inhibits the fusion of cultured mouse palatal shelves
[52]. Thus, both too little and too much EGFR signaling appear to
disturb palate morphogenesis. Besides controlling epithelial growth
and differentiation, EGFR signaling regulates the expression of
matrix metalloproteinases (MMPs) [51,53,54], which are impli-
cated in palatal morphogenesis as well as wound healing [55–60].
A causal relationship between CLP and altered wound healing
is best documented for mutations in transcription factor IRF6.
Homozygous IRF6R84C/R84C mutant mice develop epithelial
fusions between the palatal shelves and the tongue, resulting in
cleft palate [61]. In humans, mutations of this gene cause Van der
Woude (VWS) syndrome, an orofacial clefting disorder [62].
Importantly, children with VWS were reported to have an
increased risk for wound complications following cleft repair [24].
47% of VWS patients developed wound healing problems,
whereas only 19% of non-VWS children were affected. Interest-
ingly, genetic interactions between TGFA and IRF6 (i.e. co-
transmission of risk alleles with higher than expected frequency)
were reported to contribute to the risk for tooth agenesis as well as
orofacial clefts [63]. Similar interactions might occur between
IRF6 and TGFA during regenerative processes, and thus changes
in TGF-a expression and activity might contribute to altered
wound healing in a fraction of CLP patients.
Information on the role of TGF-a in wound healing is relatively
sparse. Similar to Egfr2/2 mice, Tgfa2/2 animals have wavy hair
and whiskers, pointing to an important function of the TGF-a/
EGFR pair in their differentiation [47,48]. Moreover, Tgfa2/2
mice have underdeveloped eyelids [47] and deficits in wound
epithelialization [64]. Perhaps more interesting is the fact that in
mice overexpressing TGF-a, hyperplasia of both epithelia and
fibroblasts, as well as metaplasia was observed in several organs
[65] (reviewed in [23]). Also in humans, dysregulation of Tgf-a is
associated with hyperproliferative disease and cancer. Patients
with Me´ne´trier’s disease, a hyperproliferative disorder of the
stomach, exhibit increased immunoreactivity for TGF-a in their
gastric mucosa [66], and mice overexpressing TGF-a recapitulate
all symptoms of this disease [65]. Moreover, TGF-a dysregulation
has been shown to be causally involved in carcinogenesis of the
gastrointestinal tract (reviewed in [67]). In terms of wound
regeneration, it is important to note that the administration of
EGFR inhibitors (which block EGF as well as TGF-a signaling) for
cancer treatment causes adverse cutaneous side effects, and in
some cases interferes with wound healing in humans [68,69].
Taken together, the mentioned studies point to a function of TGF-
a not only in morphogenesis of the secondary palate, but also in
wound healing and hyperproliferative disorders.
Our finding that CLP patients can be divided into two groups
based on migratory behavior of their fibroblasts in vitro appears to
be based on differential expression and activity of TGF-a. Since
the CLP patients investigated in our study are still infants, we do
not know yet whether our current in vitro results will indeed
correlate with differences between the two groups in their wound
healing behavior in vivo. It will be interesting to follow these
patients during the further course of their therapy. In more general
terms, our present findings point to an important function of TGF-
a in the migration of fibroblasts at the wound edge.
Supporting Information
Figure S1 Fluorescence staining of migrating CLP
fibroblasts for vinculin and F-actin. Cultures were fixed
24 h after scratch wounds were applied, and stained with anti-vinculin
antibody (green) and phalloidin (red), respectively. Images show a
‘‘fast’’ and an ‘‘intermediate’’ fibroblast strain at low magnification;
inserts correspond to the details depicted in Fig. 2. Scale bar, 50 mm.
(PPT)
Figure S2 Relative wound closure rates (RWC) of three
individual oral mucosal fibroblast strains. Cells were
isolated from palatal tissue grafts obtained during gingiva recession
coverage of 3 healthy adults (Probands 1–3). In vitro scratch wound
assays were performed to examine whether adult mucosal
fibroblasts fell into either the ‘‘fast’’, ‘‘intermediate’’ or ‘‘slow’’
group. The box plots indicate the median RWC of three
independent measurements. Fibroblasts from the second and third
passage were used for these experiments. SK was chosen randomly
as reference strain of the ‘‘intermediate’’ CLP group. Among the
mucosal fibroblasts, no significant difference was measured in terms
of the RWCs, which ranged from 25.9% to 32.5%. The RWCs of
Probands 2 (25.9%) and 3 (29.9%) were significantly below the one
of SK (*p,0.05). Since mucosal fibroblasts are statistically
indifferent between each other, and since their RWCs are generally
lower than that of the ‘‘intermediate’’ reference strain, on can
categorize them as part of the ‘‘slow’’ migratory group.
(PPTX)
Figure S3 Cell proliferation rate is statistically indif-
ferent between the ‘‘fast’’ and ‘‘intermediate’’ CLP
migratory groups. BrdU incorporation experiments were
performed with three randomly chosen CLP fibroblast strains
per group (see Materials and Methods). The graph indicates the
number of BrdU positive fibroblasts relative to the total number of
cells counted after 4 hours of labeling. No differences were
measured between ‘‘fast’’ and ‘‘intermediate’’ strains, which
excludes the contribution of cell proliferation to the different rates
of wound closure in vitro by the two groups.
(PPTX)
Table S1 Primers for qRT-PCR.
(DOC)
Table S2 Summary of wound healing assays in vitro.
Scratch wound assays were performed with primary dermal
fibroblasts isolated from 16 CLP patients, and with foreskin
fibroblasts isolated from 6 healthy individuals (Fsk) and 3 patients
with phimosis (Phim). For each cell strain, the table indicates the
subject’s initials, the subject group (CLP, Fsk, Phim), the median as
well as the mean percentage of relative wound closure after 24
hours (% RWC), and its standard error of the mean (SEM; n= 38
single measurements per strain). The entire data set was evaluated
by Kruskal-Wallis test followed by a pairwise Wilcoxon rank sum
test with Benjamini & Yekutieli (2001) correction for multiple
comparisons, which divided the cell strains into 3 statistically
distinct migratory groups based on their relative wound closure
ability, namely ‘‘fast’’, ‘‘intermediate’’ and ‘‘slow’’.
(DOC)
Table S3 Pairwise Wilcoxon rank sum test with Benja-
mini & Yekutieli [32] correction; data from all strains.
Shown are the p-values for differences in relative wound closure
(RWC) from pairwise comparisons of all fibroblast strains used in
this study (CLP, cleft lip/palate; Phim, Phimosis; Fsk, normal
foreskin). The initials of individual cell donors are indicated at left
and on top of the table. Note that fibroblast strains fall into three
distinct groups (red = fast, green = intermediate, blue = slow). The
p-values for RWC are not significantly different between strains
within each group, but for strains from different groups.
(PPT)
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Table S4 Pairwise Wilcoxon rank sum test with Benja-
mini & Yekutieli [32] correction; CLP strains only. Shown
are the p-values for differences in relative wound closure (RWC)
from pairwise comparisons of the CLP fibroblast strains used in
this study (outlier strain BA was excluded from analysis). The
initials of individual cell donors are indicated at left and on top of
the table. CLP fibroblast strains fall into two distinct groups
(red = fast, green= intermediate). The p-values for RWC are not
significantly different between strains within each group, but for
strains from different groups.
(PPT)
Movie S1 Life imaging of ‘‘fast’’ migratory strain XB
during 24 hours.
(MP4)
Movie S2 Life imaging of ‘‘intermediate’’ migratory
strain LP during 24 hours.
(MP4)
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